Disability Health Japan Medical Podcast Welfare

Japan Approves Muscular Dystrophy Drug Price of 304 Million Yen [Podcast Episode]

An advisory panel to Japan’s health minister decided Friday to allow public health insurance coverage for a gene therapy for muscular dystrophy beginning Feb. 20 and set the drug’s official price at about 304.97 million yen. Elevidys, a one-time treatment for Duchenne muscular dystrophy in ambulatory patients aged 3-7, will become the country’s most expensive drug.

Unknown's avatar
by Michael Gillan Peckitt
Comments 0

By Barrier Free Japan

February 15 2026

TOKYO – An advisory panel to Japan’s health minister decided Friday to allow public health insurance coverage for a gene therapy for muscular dystrophy beginning Feb. 20 and set the drug’s official price at about 304.97 million yen. 
   Elevidys, a one-time treatment for Duchenne muscular dystrophy in ambulatory patients aged 3-7, will become the country’s most expensive drug.

Episode notes:

‘Japan Approves Muscular Dystrophy Drug Price of 300 M. Yen’:

Japan Approves Muscular Dystrophy Drug Price of 300 M. Yen

0 comments on “Japan Approves Muscular Dystrophy Drug Price of 304 Million Yen [Podcast Episode]”

Leave a comment